Jump to content

Luis A. Diaz

Add links
From Wikipedia, the free encyclopedia
(Redirected from Luis Alberto Diaz, Jr.)
Luis A. Diaz Jr.
Alma mater
OccupationOncologist
EmployerMemorial Sloan Kettering Cancer Center
Websitewww.mskcc.org/cancer-care/doctors/luis-diaz-jr Edit this at Wikidata

Luis Alberto Diaz, Jr. is the Head of the Division of Solid Tumor Oncology in Memorial Sloan Kettering’s Department of Medicine.[1]

Education and career

[edit]

Diaz earned his undergraduate and medical degree at the University of Michigan and Michigan Medicine, respectively.[2] He completed his residency in internal medicine and medical oncology fellowship at Johns Hopkins School of Medicine.[1][3] Diaz was a faculty member in the Department of Oncology at the Johns Hopkins University School of Medicine.[4] He was also a member of the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins, where he worked with colleagues Bert Vogelstein, Kenneth Kinzler, Nickolas Papadopoulos, Victor Velculescu and Shibin Zhou.[4] He was also head of the Swim Across America Laboratory at Johns Hopkins.[4]

In 2017, Diaz became Head of the Solid Tumor Oncology division at Memorial Sloan Kettering. The same year, he was selected to lead the Stand Up to Cancer “Dream Team” against colorectal cancer.[5] Diaz has founded several companies that focus on genomic analyses of cancers, including Inostics,[6] PapGene,[7] and Personal Genome Diagnostics. Diaz was named to the Board of Directors of Jounce Therapeutics in 2017.[3]

Diaz was elected to the National Academy of Medicine in 2023.[8]

Research

[edit]

Diaz researched the development of a liquid biopsy that can be used to test for the presence of cancer and to monitor its response to therapy.[9][10][11][12] Also while at Hopkins, he and his colleagues developed a Pap smear to detect early-stage ovarian and endometrial cancers.[13][14] He also led a study of pembrolizumab to target tumors that share a particular biomarker called mismatch repair deficiency.[15][16][17] It was the first FDA approval for a cancer treatment based on a biomarker rather than the location in the body where the tumor originated.[15][18][19]

Awards

[edit]

See also

[edit]

References

[edit]
  1. ^ a b "Memorial Sloan Kettering Cancer Center names head of solid tumor oncology". 2017-04-26. Retrieved 2018-10-04.
  2. ^ "Colorectal Cancer Vulnerabilities Dream Team - Stand Up to Cancer". Stand Up to Cancer. Retrieved 2018-10-04.
  3. ^ a b "Luis A. Diaz Jr. Executive Profile". www.bloomberg.com. Retrieved 11 October 2018.
  4. ^ a b c "Luis A. Diaz, MD, Named Head of Solid Tumor Oncology at MSK - The ASCO Post". www.ascopost.com. American Society of Clinical Oncology. 2017-05-10. Retrieved 2018-10-04.
  5. ^ "Diaz Named Solid Tumor Oncology Division Head at Memorial Sloan Kettering". Targeted Oncology. 2017-05-04. Retrieved 2018-10-04.
  6. ^ "Sysmex Inostics - Welcome - sysmex inostics". www.sysmex-inostics.com. Retrieved 2019-02-03.
  7. ^ "PapGene, Inc. | Advancing the early detection of curable cancers". papgeneinc.com. Retrieved 2019-02-03.
  8. ^ "National Academy of Medicine Elects 100 New Members". National Academy of Medicine. 9 October 2023. Retrieved 9 October 2023.
  9. ^ Regalado, Antonio (2014-08-11). "New DNA Tests on Blood Can Catch Cancer Early". MIT Technology Review. Retrieved 2018-10-04.
  10. ^ Diehl, Frank; Schmidt, Kerstin; Choti, Michael A.; Romans, Katharine; Goodman, Steven; Li, Meng; Thornton, Katherine; Agrawal, Nishant; Sokoll, Lori (September 2008). "Circulating mutant DNA to assess tumor dynamics". Nature Medicine. 14 (9): 985–990. doi:10.1038/nm.1789. ISSN 1546-170X. PMC 2820391. PMID 18670422.
  11. ^ Diaz, Luis A.; Williams, Richard T.; Wu, Jian; Kinde, Isaac; Hecht, J. Randolph; Berlin, Jordan; Allen, Benjamin; Bozic, Ivana; Reiter, Johannes G. (2012-06-28). "The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers". Nature. 486 (7404): 537–540. Bibcode:2012Natur.486..537D. doi:10.1038/nature11219. ISSN 1476-4687. PMC 3436069. PMID 22722843.
  12. ^ Bettegowda, Chetan; Sausen, Mark; Leary, Rebecca J.; Kinde, Isaac; Wang, Yuxuan; Agrawal, Nishant; Bartlett, Bjarne R.; Wang, Hao; Luber, Brandon (2014-02-19). "Detection of circulating tumor DNA in early- and late-stage human malignancies". Science Translational Medicine. 6 (224): 224ra24. doi:10.1126/scitranslmed.3007094. ISSN 1946-6242. PMC 4017867. PMID 24553385.
  13. ^ Grady, Denise (2013-01-09). "Pap Test May Prove Useful at Detecting More Types of Cancer, Study Suggests". New York Times. Retrieved 2018-10-04.
  14. ^ Kinde, Isaac; Bettegowda, Chetan; Wang, Yuxuan; Wu, Jian; Agrawal, Nishant; Shih, Ie-Ming; Kurman, Robert; Dao, Fanny; Levine, Douglas A. (2013-01-09). "Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers". Science Translational Medicine. 5 (167): 167ra4. doi:10.1126/scitranslmed.3004952. ISSN 1946-6242. PMC 3757513. PMID 23303603.
  15. ^ a b McGinley, Laurie (2017-05-28). "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope". Washington Post. Retrieved 2018-10-04.
  16. ^ Le, Dung T.; Durham, Jennifer N.; Smith, Kellie N.; Wang, Hao; Bartlett, Bjarne R.; Aulakh, Laveet K.; Lu, Steve; Kemberling, Holly; Wilt, Cara (28 July 2017). "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade". Science. 357 (6349): 409–413. Bibcode:2017Sci...357..409L. doi:10.1126/science.aan6733. ISSN 1095-9203. PMC 5576142. PMID 28596308.
  17. ^ Le, Dung T.; Uram, Jennifer N.; Wang, Hao; Bartlett, Bjarne R.; Kemberling, Holly; Eyring, Aleksandra D.; Skora, Andrew D.; Luber, Brandon S.; Azad, Nilofer S. (2015-06-25). "PD-1 Blockade in Tumors with Mismatch-Repair Deficiency". The New England Journal of Medicine. 372 (26): 2509–2520. doi:10.1056/NEJMoa1500596. ISSN 1533-4406. PMC 4481136. PMID 26028255.
  18. ^ Kolata, Gina (2017-06-08). "Cancer Drug Proves to Be Effective Against Multiple Tumors". New York Times. Retrieved 2018-10-04.
  19. ^ Commissioner, Office of the. "Press Announcements - FDA approves first cancer treatment for any solid tumor with a specific genetic feature". www.fda.gov. Retrieved 2019-02-03.
  20. ^ a b c "AACR Team Science Award". www.aacr.org. American Association for Cancer Research. Retrieved 2018-10-04.
  21. ^ "The American Society for Clinical Investitagation". Retrieved 2018-10-04.
[edit]
Retrieved from "https://wiki.riteme.site/w/index.php?title=Luis_A._Diaz&oldid=1179431436"